

SURVEY OF THE QUALITY OF MEDICINES IDENTIFIED BY THE UNITED NATIONS COMMISSION ON LIFE SAVING COMMODITIES FOR WOMEN AND CHILDREN



Survey of the quality of medicines
identified by the United Nations
Commission on Life-Saving Commodities
for Women and Children

2015



WHO Library Cataloguing-in-Publication Data

Survey of the quality of medicines identified by the United Nations commission on life saving commodities for women and children.

1. Drugs, Essential - standards. 2. Drug Industry. 3. Women. 4. Child. 5. Surveys and Questionnaires. I. World Health Organization.

ISBN 978 92 4 151111 7

(NLM classification: QV 771)

©World Health Organization 2016

All rights reserved. Publications of the World Health Organization are available on the WHO website (<http://www.who.int>) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website (http://www.who.int/about/licensing/copyright_form/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in the EU

Acknowledgements

The survey was organized by the Prequalification Team (WHO PQT) of the World Health Organization Department of Essential Medicines and Health Products as an activity sponsored by the United Nations Commission on Life-Saving Commodities for Women and Children. The survey was developed, organized and the report was written by Jitka Sabartova with principal support of Milan Smid and Deus Mubangizi, all members of the WHO PQT.

This report is the result of a survey carried out by WHO in cooperation with the Ministries of Health and National Medicines Regulatory Authorities of Burkina Faso, Kenya, Madagascar, Nepal, Nigeria, Tajikistan, Tanzania, Uganda, Viet Nam and Zimbabwe. WHO thanks these Ministries of Health and National Medicines Regulatory Authorities for their important cooperation and assistance. Acknowledgement is due to the country teams and to individuals who developed the national sampling plans and organized collection and dispatch of samples, in particular to:

Nerwaya Eve Ramata Ouedraogo, Responsible of the Post-marketing Quality Control of Health Products, Direction générale de la pharmacie du médicament et des laboratoires, Ministère de la Santé, Burkina Faso

Edward Abwao, Division of Medicines Information and Pharmacovigilance, Pharmacy and Poisons Board, Kenya

Robin Razakarivelo, Head of the Department of Quality Control, Agence du Médicament de Madagascar, Ministère de la Santé Publique, Madagascar

Mohan Prasad Amatya, Director of the National Drug Laboratory, Department of Drug Administration, Ministry of Health and Population, Government of Nepal

Ibrahim Otulukpe Ali, Deputy Director – Technical Services, National Agency for Food Administration and Control, Nigeria

Salomudin Isupov, Ministry of Health of the Republic of Tajikistan

Grace Mng'ong'o Shimwela, Senior Drug Inspector, Post Marketing Surveillance and Counterfeit Coordination, Tanzania Food and Drug Authority, Tanzania

Kenneth Kiiza, Regional Inspector of Drugs, National Drug Authority, Uganda

Thi Phuong Thanh Tran, Drug Administration of Viet Nam, Ministry of Health, Viet Nam

Thi Thu Huong Do, Officer at Drug Quality Management Department, Drug Administration of Viet Nam, Ministry of Health, Viet Nam

Caroline Dandira, Chief Regulatory Officer for Licensing, Medicines Control Authority of Zimbabwe.

WHO also thanks the following staff of Ministries of Health and National Medicines Regulatory Authorities in the participating countries for their valuable cooperation during the results analysis:

Daniel Dori and Gisèle Sanou (Burkina Faso); Anthony Martin Toroitich (Kenya); Harisoa Rabenandrianina (Madagascar); Gajendra Bahadur Bhujju (Nepal); Kehinde Mamudu (Nigeria); Mary Masanja (Tanzania); Farida Khaukha (Uganda); Tinashe Gono, Tariro Makamure, Nyasha Maregere, Emma Mudzura and Munakandafa Mutasa (Zimbabwe).

The following National Professional Officers, Programme Officers and other staff members from WHO regional and country offices provided invaluable assistance in preparing the survey in countries:

Arsène Ouedraogo and Daogo Sosthene Zombre (Burkina Faso); Regina Munyiva Mbindyo (Kenya); Yugesh Rajbhandari and Silas Rai (Nepal); Ogori Taylor (Nigeria); Lola Yuldasheva (Tajikistan);

Rose Shija Muhangwa (Tanzania); Joseph Ngobi Mwoga (Uganda); Socorro Escalante (Viet Nam); Stanley Munyaradzi Midzi (Zimbabwe); Jean Baptiste Nikiema (AFRO); Nina Sautenko (EURO); Kathleen Anne Holloway (SEARO); Klara Tisocki (WPRO).

Special thanks are due to the teams of WHO country offices in Tanzania and Zimbabwe and to the Inter-country Support Team for Eastern and Southern Africa led by Thomas Lapnet-Moustapha for the organization of the meetings with focal persons during the survey.

Acknowledgement is due to Theo Dekker and Robyn Isaacson, expert consultants, who helped with the interpretation of test results. Rutendo Kuwana (WHO PQT) provided valuable comments to the report and Monika Zwegarth (consultant) provided editing services.

WHO also thanks Stada-VN Joint Venture Company Ltd, Viet Nam for kind provision of testing methods and specifications for mifepristone injection.

The survey has been organized and this document has been produced with the financial assistance of the United Nations Commission on Life-Saving Commodities for Women and Children. The views expressed herein are those of the authors and can in no way be taken to reflect the official opinion of the Commission.

Contents

Executive summary.....	9
1. Introduction	13
1.1 Background	13
1.2 Objectives of the survey	15
2. Methodology	17
2.1 Survey period	17
2.2 Selection of medicines for sampling and testing	17
2.3 Participating countries	21
2.4 Selection of sample collection sites	21
2.5 Sample collection and transportation	22
2.6 Testing laboratories	23
2.7 Quality tests conducted and test methods and specifications used	23
2.8 Compliance of samples with standards	25
3. Results	26
3.1 Overview of samples collected	26
3.1.1 Medicines collected	26
3.1.2 Manufacturers and batches	29
3.1.3 Sampling sites	32
3.1.4 Storage and transportation conditions	32
3.2 Registration status of sampled products	33
3.3 WHO prequalification status of sampled products	34
3.4 Compliance with specifications	36
3.4.1 Overview of results	36
3.4.2 Results for individual medicines	39
3.4.2.1 <i>Oxytocin injection (Appendix 3)</i>	39
3.4.2.2 <i>Magnesium sulfate injection (Appendix 4)</i>	45
3.4.2.3 <i>Gentamicin injection (Appendix 5)</i>	46
3.4.2.4 <i>Procaine benzylpenicillin injection (Appendix 6)</i>	48
3.4.2.5 <i>Ampicillin injection (Appendix 7)</i>	48
3.4.2.6 <i>Ceftriaxone injection (Appendix 8)</i>	50
3.4.2.7 <i>Dexamethasone phosphate injection (Appendix 9)</i>	51
3.4.2.8 <i>Amoxicillin dispersible tablets (Appendix 10)</i>	52
3.4.2.9 <i>Zinc containing products (Appendix 11)</i>	52
3.4.2.10 <i>Levonorgestrel tablets (Appendix 12)</i>	53
3.4.2.11 <i>Mifepristone tablets (Appendix 13)</i>	54
4. Discussion	55
4.1 Testing methods and data quality	55
4.2 Limitations of methodology	55
4.3 Selection of participating countries	56
4.4 Availability of target medicines for sample collection in surveyed countries	56

4.5	Medicines' strengths available for sample collection in surveyed countries	57
4.6	Information on the strength and API on the label	58
4.7	Manufacturers.....	59
4.8	Storage conditions in sites of sample collection	59
4.9	Overall quality findings.....	59
4.10	Quality of individual sampled medicines.....	65
4.11	Regulatory actions.....	70
4.12	Recommendations from survey wrap-up meeting	70
5.	Conclusions	73
6.	References.....	77
	Appendices.....	78
Appendix 1	Survey protocol.....	78
Appendix 2	Manufacturers of samples collected for individual medicines	102
Appendix 3	Oxytocin injection – test results.....	110
Appendix 4	Magnesium sulfate injection – test results	114
Appendix 5	Gentamicin injection.....	116
Appendix 6	Procaine benzylpenicillin injection – test results.....	121
	Procaine benzylpenicillin + benzylpenicillin injection – test results.....	122
Appendix 7	Ampicillin injection – test results	123
Appendix 8	Ceftriaxone injection - test results	127
Appendix 9	Dexamethasone injection - test results.....	131
Appendix 10	Amoxicillin dispersible tablets - test results	134
Appendix 11	Zinc tablets - test results	136
	Zinc sulfate syrup - test results	139
Appendix 12	Levonorgestrel tablets - test results.....	140
Appendix 13	Mifepristone tablets - test results	142

List of tables

Table 1	Target commodities	13
Table 2	Laboratories performing quality testing.....	23
Table 3	Specifications and methods used for testing.....	24
Table 4	Numbers of samples per medicine in total and in different strengths collected in the survey, and corresponding numbers of manufacturers.....	27
Table 5	Summary of numbers of samples and products collected in individual countries.....	28
Table 6	Samples of locally manufactured products	29
Table 7	Manufacturers with samples taken of multiple medicines and/or in multiple countries.....	31
Table 8	Numbers of collection sites in individual countries with numbers of collected samples	32
Table 9	Storage conditions at sampling sites, as recorded by collectors	33

Table 10	Registration status of samples.....	34
Table 11	WHO-prequalified products relevant to this quality survey	35
Table 12	Breakdown of testing outcomes for each medicine by country	37
Table 13	Number of samples which failed specific quality tests.....	38
Table 14	Presence of preservatives in collected oxytocin injection samples	43
Table 15	Storage temperature declared by manufacturers of collected oxytocin injection samples and the shelf-life.....	44
Table 16	Oxytocin injection samples – storage conditions and outcomes of testing for collected samples.....	44
Table 17	Storage conditions at the sites where non-compliant samples were collected and results found	52
Table 18	Quality of domestically produced products	63
Table 19	Quality of products unregistered in the country of collection	64

List of figures

Figure 1	Numbers of locally manufactured and imported zinc-containing products collected in countries	30
Figure 2	Appearance of different types of ampoules collected for one oxytocin injection sample at one collection site and identified by the same batch number	39
Figure 3	HPLC chromatogram of a oxytocin injection sample with no related substances detected	40
Figure 4	HPLC chromatogram of an oxytocin injection sample with a high amount of related substances detected.....	41
Figure 5	Content of oxytocin and related substances in individual samples presented as a percentage of the declared oxytocin content against time elapsed between manufacture and testing	42
Figure 6	Typical HPLC chromatogram obtained with gentamicin injection samples of 8 manufacturers and reference substance Gentamicin BPCRS	47
Figure 7	Typical HPLC chromatogram obtained with gentamicin injection samples of 15 other manufacturers	47
Figure 8	Example of HPLC chromatogram of an ampicillin sample compliant with specifications	49

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_27128

